At JP Morgan Week 2025, pharmaphorum’s Jonah Comstock took a quick detour to Grove.AI’s San Francisco offices to talk to ...

Since then, Biogen decided to opt out of their partnership on essential tremor candidate SAGE-324 after disappointing results ...

The scale of the decline in Veru's shares despite the positive result may reflect the amplified expectations of investors for ...

Depemokimab is a follow-up to GSK's Nucala (mepolizumab), a once-monthly IL-5 inhibitor approved for severe asthma, CRSwNP, ...

Digital tools, powered by intuitive design, AI, and customer centricity, offer a unique opportunity to bridge the trust gap ...

Artificial intelligence startup Quibim has raised $50 million in first-round financing to support the rollout of its ...

The word on San Francisco’s famously hilly streets is that big pharma is ready to go shopping in 2025, following a flurry of ...

Over 6.3 million patients make up the NHS backlog for consultant-led elective care, which reached 7,573,212 in September 2024 ...

AstraZeneca and Daiichi Sankyo have claimed their seventh FDA approval for Enhertu, getting the go-ahead for the blockbuster drug as a second-line treatment for patients with HER2-low and ...